Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
Conditions: Pancreatic Ductal Adenocarcinoma; Refractory Non-Small Cell Lung Cancer Interventions: Drug: Daratumumab; Biological: KRAS vaccine; Drug: Nivolumab Sponsors: Georgetown University; Bristol-Myers Squibb; Janssen, LP; Targovax ASA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Lung Cancer | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Research | Vaccines